Cholamandalam Investment and Finance Company (511243) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
29 Oct, 2026Executive summary
Q2 FY27 disbursements rose 47% YoY to ₹35,872 crore; AUM reached ₹2,68,009 crore, up 25%, and PAT increased 41% to ₹1,630 crore.
H1 disbursements grew 34% to ₹65,484 crore; PBT rose 43% to ₹4,409 crore and PAT rose 43% to ₹3,284 crore.
Financial highlights
Q2 total income rose 23% YoY to ₹9,367 crore and net income increased 24% to ₹5,037 crore; Q2 PBT rose 40% to ₹2,188 crore.
Q2 expenses increased 22% to ₹1,975 crore, while net credit losses declined 3% to ₹874 crore; H1 net income rose 26% to ₹9,967 crore.
H1 total income rose 23% to ₹18,300 crore and PBT increased 43% to ₹4,409 crore; reported H1 ROE was 20.3%.
Outlook and guidance
FY growth guidance remained 20%-23% on a steady-state basis; management said initial targets of 25% growth and 1.4% net credit cost had been achieved at H1, with H2 potentially stronger.
Management expected seasonally stronger H2 performance, with growth rates potentially moderating against a stronger base; October vehicle disbursements were up 18%-20% YoY.
CSEL unsecured business loans and consumer durable/digital lending were delivering close to 3.6% ROA, with combined pretax ROA expected to exceed 4%.
Floating-rate books, including affordable housing, LAP and SME, were expected to be repriced in Q3; aggregate yield could decline at least 10 bps as funding costs rise.
Affordable housing finance AUM was expected to grow 19%-21% in FY27; management expected mortgage businesses to gain share over 3-4 years.
Latest events from Cholamandalam Investment and Finance Company
- Robust financials, a forceful rebuttal and improving Q3 disbursement momentum.511243
Status update - PPOP grew 56%, but pandemic-driven loan losses cut Q1 PAT 24%.511243
Q1 21/22 - Strong Q2 growth and improving asset quality, with COVID-related credit risk still elevated.511243
Q2 21/22 - Disbursements jumped 267% and PAT grew 73%, with Stage 3 improving to 4.16%.511243
Q1 22/23 - Record disbursements and AUM growth offset a tougher Q2 PAT comparison.511243
Q2 22/23 - Q3 disbursements +68%, AUM +31% and standalone PAT +31% YoY.511243
Q3 22/23 - Disbursements surged 50% as higher funding costs tempered Q1 profit growth.511243
Q1 23/24 - FY22 profit rose 42% as record disbursements fueled lending growth.511243
Q4 21/22 - Record FY23 lending growth and improved asset quality supported higher profit.511243
Q4 22/23